Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has announced inducement grants under NASDAQ Listing Rule 5635(c)(4). The company granted stock options to purchase up to 50,000 shares of common stock to four new employees under its 2023 Inducement Plan.
The stock options feature a four-year vesting schedule, with 25% of shares vesting after the first year and the remaining shares vesting monthly at 1/48th over the subsequent 36 months. Continued employment with Syndax is required through applicable vesting dates.
Details
News Market Reaction – SNDX
The recorded move for SNDX in the trading session of this news was -2.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, 2025 the Company granted inducement awards to purchase up to 50,000 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.